Vetanco International Acknowledgment for Sherry Layton, Vetanco Scientific Director

Sherry Layton, Vetanco Scientific Director, will be awarded in the 12th International Conference on Emerging Infectious Diseases

Vaccines Conference-2022, Global Conference on Vaccines Research and Development

Frontiers Animal Production With Restrictive Use of Antibiotics to Contain Antimicrobial Resistance in Sweden—A Qualitative Study

Sherry Layton - Chief Executive Officer - Vetanco USA

PDF) Pathogenesis, Molecular Genetics, and Genomics of Mycobacterium avium subsp. paratuberculosis, the Etiologic Agent of Johne's Disease

Vaccines Conference-2022, Global Conference on Vaccines Research and Development

Frontiers Evaluation of a Novel Mucosal Administered Subunit Vaccine on Colostrum IgA and Serum IgG in Sows and Control of Enterotoxigenic Escherichia coli in Neonatal and Weanling Piglets: Proof of Concept

Frontiers Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

Vetanco International Acknowledgment for Sherry Layton, Vetanco Scientific Director

Sherry Layton - Chief Executive Officer - Vetanco USA

Sherry Layton - Chief Executive Officer - Vetanco USA

Vaccines Conference-2022, Global Conference on Vaccines Research and Development

PDF) Effects of Different Nutritional Zinc Forms on the Proliferation of Beneficial Commensal Microorganisms

Frontiers Evaluation of a Novel Mucosal Administered Subunit Vaccine on Colostrum IgA and Serum IgG in Sows and Control of Enterotoxigenic Escherichia coli in Neonatal and Weanling Piglets: Proof of Concept

Frontiers Differential Effects of Bacitracin Methylene Disalicylate (BMD) on the Distal Colon and Cecal Microbiota of Young Broiler Chickens